Lilly gave one patient compassionate access to retatrutide, and Congress wants to know who

Eli Lilly and the Food and Drug Administration allowed one patient, a 79-year-old man, to receive Lilly's experimental obesity drug retatrutide through the FDA's compassionate use program, and Democratic lawmakers are now pressing the administration over who that patient is ^[1][2].

STAT reported on June 23 that the request was made in April, when the patient was 79, according to three sources familiar with the matter who spoke anonymously because they feared reprisals ^[1]. Those sources said the case drew the interest of top health officials, which suggested the recipient was well connected ^[1]. The reporting points to a single instance in which retatrutide was provided for compassionate use ^[1].

Compassionate use, also called expanded access, is a pathway that gives patients with serious and immediately life-threatening medical conditions access to treatments that are not yet approved ^[1][2]. The patient has refractory obesity, obstructive sleep apnea and pulmonary hypertension ^[2].

Retatrutide is not approved by the FDA. In trials it has produced weight loss on the scale seen with bariatric surgery, and while millions of Americans with obesity wait for it, some have tried to get it through what STAT described as sketchy means ^[1].

On June 25, Sen. Maggie Hassan (D-N.H.) sent a letter to Health and Human Services Secretary Robert Kennedy Jr. seeking documents about the single-person access ^[2]. The letter asks, "Was it President Trump?" ^[2]. Rep. Lieu also raised questions about whether the patient was the president or another prominent figure ^[2].

The patient has not been identified publicly, and the White House, HHS, Lilly and the FDA have not said who received the drug ^[1][2]. No response from the administration to the lawmakers' questions has been reported ^[2].

Why it matters for patients

Compassionate use is a narrow path meant for people facing serious, immediately life-threatening illness, and it requires both a drugmaker and the FDA to agree ^[1][2]. Only one patient received retatrutide this way, so the case does not open a route to the drug for anyone else ^[1].

Retatrutide is still experimental. It cannot be prescribed and is not dispensed by pharmacies ^[1]. STAT reported that some people are trying to buy it through sketchy means, which means the product they get has not been reviewed by the FDA ^[1].

The questions from Congress are about process and fairness, meaning who gets special access and how that decision is made, not about whether retatrutide works ^[2]. That distinction matters for people who take FDA-approved GLP-1 medicines and are watching how experimental obesity drugs are handled before approval.

What happens next

Lawmakers sent their request for documents on June 25 ^[2]. A deadline for a response, and any reply from HHS, have not been reported ^[2]. No date has been reported for an FDA decision on retatrutide, and Lilly has not disclosed whether it will offer the drug through any broader access program ^[1].